Franklin Berger

Franklin Berger Overview

  • Investor Type
  • Angel
  • Investments
  • 2
  • Portfolio
  • 1
  • Exits
  • 1

Franklin Berger General Information


Mr. Franklin Berger serves as a Board of Director at Proteostasis Therapeutics. He joined Proteostasis Therapeutics Board of Directors in February 2016. Mr. Berger is a consultant to biotechnology industry participants, including major biopharmaceutical firms, mid-capitalization biotechnology companies, specialist asset managers and venture capital companies, providing business development, strategic advisory, financing, partnering and royalty acquisition advice. Mr. Berger is also a biotechnology industry analyst with over 25 years of experience in capital markets and financial analysis. Mr. Berger worked at Sectoral Asset Management as a co-founder of the small-cap focused NEMO Fund from January 2007 through May 2008. From May 1998 to March 2003, he served at J.P. Morgan Securities, most recently as Managing Director, Equity Research and Senior Biotechnology Analyst. Previously, Mr. Berger served in similar capacities at Salomon Smith Barney and Josephthal & Co. Mr. Berger also serves on the boards of directors of BELLUS Health, Inc. (OTCPK: BLUSF), ESSA Pharma, Inc. (NASDAQ: EPIX), Immune Design Corp. (NASDAQ: IMDZ) and Five Prime Therapeutics, Inc. (NASDAQ: FPRX), each of which is a public biotechnology company. Mr. Berger formerly served on the boards of Seattle Genetics, Inc. (NASDAQ: SGEN), Aurinia Pharmaceuticals, Inc. (NASDAQ: AUPH) and Emisphere Technologies, Inc., BioTime, Inc. and VaxGen, Inc., each of which were public biopharmaceutical companies during Mr. Berger's service as a director. Mr. Berger received a B.A. in International Relations and an M.A. in International Economics both from Johns Hopkins University and an M.B.A. from the Harvard Business School. He is also a Chartered Financial Analyst.

Contact Information

Primary Investor Type
Angel (individual)
Primary Office
  • 80 Guest Street
  • 5th Floor
  • Boston, MA 02135
  • United States
+1 (617) 000-0000

Franklin Berger Investments (2)

Company Name Deal Date Deal Type Deal Size Industry Company Stage Lead Partner
Amphivena Therapeutics 24-Sep-2019 Later Stage VC 0000 Biotechnology Generating Revenue 00000000 000000
0000000 0000000000 08-Feb-2017 00000 00000 00.000 Biotechnology Generating Revenue
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Franklin Berger Exits (1)

To view Franklin Berger‘s complete exit history, request access »
Company Name Exit Date Exit Type Exit Size
0000000 0000000000 14-May-2019 000 0000

Franklin Berger Team (1)

Name Title Deals Funds Boards Office
Franklin Berger Angel Investor 0 0 Boston, MA